Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GILD | NASDAQ | USD | Real-time | |
0QYQ | London | USD | Real-time | |
GILD | Mexico | MXN | Delayed | |
GGILD | Milan | EUR | Real-time | |
GILD | Xetra | EUR | Delayed | |
GILD | Frankfurt | EUR | Delayed | |
GILD | TradeGate | EUR | Delayed | |
GILDm | Buenos Aires | ARS | Delayed | |
GILD34 | B3 | BRL | Delayed | |
GILD | Vienna | EUR | Real-time | |
GILD | Lima | USD | Delayed |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Name | Age | Since | Title |
---|---|---|---|
Daniel P. O'Day | 57 | 2019 | Chairman & CEO |
Paul Berg | 97 | 1998 | Member of Scientific Advisory Board |
Grace E. Colon | 56 | 2023 | Chairman of the Board |
Joel R. Huff | - | - | Chairperson of Scientific Advisory Board |
Kelly A. Kramer | 56 | 2016 | Independent Director |
Javier J. Rodriguez | 53 | 2020 | Independent Director |
Sandra J. Horning | 75 | 2020 | Independent Director |
Jeffrey A. Bluestone | 71 | 2020 | Independent Director |
Ted W. Love | 65 | 2024 | Independent Director |
Jacqueline K. Barton | 71 | 1989 | Independent Director |
Eugene R. Schiff | - | - | Member of the Scientific Advisory Board |
John W. Mellors | 86 | - | Member of the Scientific Advisory Board |
Harish M. Manwani | 71 | 2018 | Independent Director |
Eric J. Topol | 70 | - | Member of Scientific Advisory Board |
Robert A. Harrington | 63 | - | Member of the Scientific Advisory Board |
Paul E. Klotman | - | - | Member of the Scientific Advisory Board |
Francis V. Chisari | - | - | Member of the Scientific Advisory Board |
Robert T. Schooley | - | - | Member of the Scientific Advisory Board |
Nezam H. Afdhal | 67 | - | Member of Scientific Advisory Board |
Mark C. Genovese | - | - | Member of Scientific Advisory Board |
Malcolm MacCoss | 76 | - | Member of Scientific Advisory Board |
Anthony Welters | 69 | 2020 | Lead Independent Director |
Kenneth C. Anderson | 73 | - | Member of the Scientific Advisory Board |
Brian J. Druker | 68 | - | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review